South Korean (KOSPI) Life Sciences Industry Analysis

Industry Valuation and Performance

Has the South Korean Life Sciences Industry valuation changed over the past few years?

Current Industry PE: Investors are more pessimistic on the industry, considering it's trading at a PE ratio of 26.3x which is lower than its 3-year average PE of 52.7x. It appears they believe that earnings will not grow as fast as they have historically.

Past Earnings Growth: The earnings for companies in the Life Sciences industry have grown 39% per year over the last three years, and revenues for these companies have grown 32% per year. This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the South Korean Life Sciences industry?

Industry PE: Investors are most optimistic about the Clinical Research and Equipment industry even though it's trading below its 3-year average PE ratio of 52.7x. This is likely because analysts are expecting annual earnings growth of 17%, which is higher than its past year's earnings growth of 15% per year.

Forecasted Growth: Analysts are most optimistic on the Clinical Research and Equipment industry, expecting annual earnings growth of 17% over the next 5 years. This is roughly in line with its past earnings growth rate.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?